Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/30186
DC FieldValueLanguage
dc.contributor.authorIskra Velevskaen_US
dc.contributor.authorJovana Aleksoven_US
dc.contributor.authorEvgenija Mihajloskaen_US
dc.contributor.authorAleksandar Dimkovskien_US
dc.contributor.authorIrina Panovska-Stavridisen_US
dc.contributor.authorMilena Stevanovicen_US
dc.contributor.authorAleksandra Grozdanovaen_US
dc.date.accessioned2024-05-15T08:02:25Z-
dc.date.available2024-05-15T08:02:25Z-
dc.date.issued2022-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/30186-
dc.language.isoenen_US
dc.relation.ispartofMacedonian pharmaceutical bulletinen_US
dc.titleUse of tocilizumab for treatment of COVID-19 from off-label to extended indicationen_US
dc.typeOtheren_US
dc.identifier.doi10.33320/maced.pharm.bull.2022.68.03.277-
item.grantfulltextnone-
item.fulltextNo Fulltext-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Pharmacy-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Other
Show simple item record

Page view(s)

21
checked on Jul 11, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.